Treatment delay and treatment pattern modifications among epithelial ovarian cancer patients during the COVID-19 pandemic: A retrospective cohort study.
J Surg Oncol
; 126(7): 1155-1161, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-1976748
ABSTRACT
BACKGROUND AND OBJECTIVES:
The coronavirus disease 2019 (COVID-19) pandemic disrupted healthcare access and medical treatment, including oncological care. Treatment delay in ovarian cancer could impact survival. We aimed to assess if there were delays and treatment changes in a cohort of epithelial ovarian cancer patients.METHODS:
A retrospective cohort of epithelial ovarian cancer patients included cases diagnosed during the first 22 months of the COVID-19 pandemic in the state of Sao Paulo and those diagnosed in the 22 months preceding the outbreak. Time-to-treat was measured in days. In each group, surgery and chemotherapy proportions were assessed according to healthcare insurance status.RESULTS:
A 56.2% reduction in epithelial ovarian cancer diagnosis was identified during the pandemic group compared to the prepandemic group; fewer patients were diagnosed in stage I (p < 0.01). Time-to-treat increased from 18.9 to 23 days (p < 0.01). Surgery in the public sector fell from 74.6% to 65.3% during the pandemic, compared to 87.1% to 68.8% in the private sector.CONCLUSION:
There were fewer overall diagnoses, reduced stage I diagnosis, increased time-to-treat, and a reduction in the proportion of patients submitted to surgery. Brazil's public healthcare system demonstrated a higher resiliency to treatment change than the private sector.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Limits:
Female
/
Humans
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
J Surg Oncol
Year:
2022
Document Type:
Article
Affiliation country:
Jso.27048
Similar
MEDLINE
...
LILACS
LIS